CAJ | 학술논문

目的：探讨阿托伐他汀在感染性休克治疗中的应用效果及安全性。方法将67例感染性休克患者按随机数字表法分为治疗组34例和对照组33例，对照组采用常规药物治疗，观察组在对照组基础上加用阿托伐他汀。比较两组治疗前后患者炎性反应指标、细胞因子水平变化，多器官功能障碍综合征（ MODS）病例数，28 d死亡病例数，不良反应发生情况。结果治疗组心率、呼吸频率、白细胞计数明显优于对照组，细胞因子改善水平显著优于对照组，差异均有统计学意义（t＝4．181、3．622、4．879，均P＜0．05）；治疗组MODS发生率明显低于对照组（χ2＝7．153，P＜0．05）；治疗组平均住院天数为（9．3±3．1） d，明显少于对照组的（12．4±3．3）d（t＝3．964，P＜0．05）。两组不良反应发生率差异有统计学意义（χ2＝4．566，P＜0．05）；两组患者28 d病死率差异无统计学意义（χ2＝3．345，P＞0．05）。结论阿托伐他汀可以减轻感染性休克患者炎性反应程度，降低MODS发生率，对患者预后可能存在潜在益处，但仍需进一步临床研究加以证实。
목적：탐토아탁벌타정재감염성휴극치료중적응용효과급안전성。방법장67례감염성휴극환자안수궤수자표법분위치료조34례화대조조33례，대조조채용상규약물치료，관찰조재대조조기출상가용아탁벌타정。비교량조치료전후환자염성반응지표、세포인자수평변화，다기관공능장애종합정（ MODS）병례수，28 d사망병례수，불량반응발생정황。결과치료조심솔、호흡빈솔、백세포계수명현우우대조조，세포인자개선수평현저우우대조조，차이균유통계학의의（t＝4．181、3．622、4．879，균P＜0．05）；치료조MODS발생솔명현저우대조조（χ2＝7．153，P＜0．05）；치료조평균주원천수위（9．3±3．1） d，명현소우대조조적（12．4±3．3）d（t＝3．964，P＜0．05）。량조불량반응발생솔차이유통계학의의（χ2＝4．566，P＜0．05）；량조환자28 d병사솔차이무통계학의의（χ2＝3．345，P＞0．05）。결론아탁벌타정가이감경감염성휴극환자염성반응정도，강저MODS발생솔，대환자예후가능존재잠재익처，단잉수진일보림상연구가이증실。
Objective To explore the clinical efficacy and safety of atorvastatin in the treatment of patients with septic shock.Methods 67 patients with septic shock were randomly divided into the treatment group (34 cases) and control group(33 cases).The control group was treated with conventional therapy ,and the observation group was administered with atorvastatin based on the control group .Before and after treatment ,the inflammatory index ,cytokines levels,the number of MODS cases,the number of deaths at 28th day,and the incidence of adverse reactions were com-pared between the two groups .Results The heart rate ,respiratory rate ,white blood cell count of the treatment group were significantly better than the control group ,the cytokines levels were significantly lower than the control group ,the differences were statistically significant (t=4.181,3.622,4.879,all P<0.05).The incidence rate of MODS of treat-ment group was significantly lower than that of the control group (χ2 =7.153,P<0.05).The average hospital stay of the treatment group was (9.3 ±3.1)d,which was significantly less than (12.4 ±3.3)d of the control group(t=3.964,P<0.05).The incidence rate of adverse reaction in the treatment group was significantly lower than that of the control group(χ2 =4.566,P<0.05).The 28 d mortality rate of the two groups had no significant difference (χ2 =3.345,P>0.05).Conclusion Atorvastatin can effectively reduce the degree of inflammatory reaction in patients with septic shock ,decrease the incidence of MODS , and has potential benefits on the prognosis of patients , but still need to be further confirmed by clinical research .